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Identification of Functional Variants for Cleft Lip
with or without Cleft Palate in or near PAX7, FGFR2,
and NOG by Targeted Sequencing of GWAS Loci
Elizabeth J. Leslie,1,22,* Margaret A. Taub,2,22 Huan Liu,3,4 Karyn Meltz Steinberg,5 Daniel C. Koboldt,5
Qunyuan Zhang,6 Jenna C. Carlson,7 Jacqueline B. Hetmanski,8 Hang Wang,8 David E. Larson,5
Robert S. Fulton,5 Youssef A. Kousa,9 Walid D. Fakhouri,10 Ali Naji,10 Ingo Ruczinski,2
Ferdouse Begum,8 Margaret M. Parker,8 Tamara Busch,11 Jennifer Standley,11 Jennifer Rigdon,11
Jacqueline T. Hecht,12 Alan F. Scott,13 George L. Wehby,14 Kaare Christensen,15 Andrew E. Czeizel,16
Frederic W.-B. Deleyiannis,17 Brian C. Schutte,18 Richard K. Wilson,5 Robert A. Cornell,19
Andrew C. Lidral,3 George M. Weinstock,5,20 Terri H. Beaty,8 Mary L. Marazita,1,21,*
and Jeffrey C. Murray11
Although genome-wide association studies (GWASs) for nonsyndromic orofacial clefts have identified multiple strongly associated
regions, the causal variants are unknown. To address this, we selected 13 regions from GWASs and other studies, performed targeted
sequencing in 1,409 Asian and European trios, and carried out a series of statistical and functional analyses. Within a cluster of strongly
associated common variants near NOG, we found that one, rs227727, disrupts enhancer activity. We furthermore identified significant
clusters of non-coding rare variants near NTN1 and NOG and found several rare coding variants likely to affect protein function,
including four nonsense variants in ARHGAP29.We confirmed 48 de novo mutations and, based on best biological evidence available,
chose two of these for functional assays. One mutation in PAX7 disrupted the DNA binding of the encoded transcription factor in an
in vitro assay. The second, a non-coding mutation, disrupted the activity of a neural crest enhancer downstream of FGFR2 both
in vitro and in vivo. This targeted sequencing study provides strong functional evidence implicating several specific variants as primary
contributory risk alleles for nonsyndromic clefting in humans.Introduction
Genome-wide association studies (GWASs) have collec-
tively identified thousands of genetic risk factors for
various complex human diseases. Although the associated
SNPs identified through GWASs might themselves be func-
tional, it is likely that many are in linkage disequilibrium
with causal variants. It remains a major challenge to
identify such causal variants because the most significant
SNPs are frequently located in non-coding regions of the
genome. A second limitation is that GWASs focus on
common variants, even though the genetic architecture
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The Amecombination of common, rare, and de novo risk alleles.
Targeted sequencing of large genomic regions achieving
genome-wide significance creates the opportunity to
address both of these issues. Requisite for these studies is
a detailed catalog of genetic variation at each locus.
We undertook a targeted sequencing study of regions
associated with orofacial clefts (MIM 119530), specifically
focusing on nonsyndromic cleft lip with or without cleft
palate (NSCL/P). NSCL/P affects approximately 1 in 700
live births and exhibits a complex etiology due to multiple
genetic and environmental risk factors.1 As is true for
many complex traits, substantial progress in gene identifi-
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of GWASs.2 Prior to GWASs only one gene, IRF6 (MIM
607119), had been consistently shown to have common
variants associated with increased risk of NSCL/P.3,4
After genome-wide linkage studies,5 four GWASs,6–9 and
a GWAS meta-analysis,10 12 loci associated with NSCL/P
are now identified and replicated on chromosomes 1p22,
1p36, 2p21, 3p11.1, 8q21.3, 8q24, 9q22, 10q25, 15q22,
17p13, 17q22, and 20q12.
To deepen our understanding of the genetic architecture
of NSCL/P, we sequenced more than 4,000 participants
for 13 genomic intervals implicated in NSCL/P. We used
a case-parent trio design, which has many advantages
including improved quality of genotype calls and haplo-
types, accurate calling of de novo mutations, and robust-
ness to population stratification in statistical analyses.
These 13 regions included 9 regions selected as high-prior-
ity candidates from GWASs and/or genome-wide linkage
studies and 4 regions containing candidate genes with
prior compelling evidence of rare variants contributing
to NSCL/P. This is the first study to perform targeted
sequencing of NSCL/P GWAS regions and is among the
first to sequence the complete GWAS intervals, including
non-coding and coding DNA, for any complex disease or
trait. Our international cohort of participants consists of
case-parent trios, which allows us to accurately identify
de novo mutations and makes it possible to search for
the contributions of both rare and common variants as
risk alleles for NSCL/P. Here we present the highlights
of our study that demonstrate the strength of targeted
sequencing to identify functional variants.Subjects and Methods
Samples
The study population included 1,498 case-parent trios recruited by
several research groups with samples coming from individuals of
Asian or European ancestry from Europe, the United States, China,
and the Philippines (Table S1). After QC as described below, 1,409
of the trios (4,227 individuals) were included in the final analyses.
Approval for all research work was obtained from the Institutional
Review Boards of participating institutions (both US and foreign)
and informed consent was obtained from parents of minor chil-
dren and from all affected individuals old enough to give their
own consent. Affected subjects were diagnosed as having cleft
lip (CL) or cleft lip with cleft palate (CLP) based on physical
exam. Individuals with other congenital anomalies, recognized
CL/P syndromes, or developmental delays were excluded from
this study.
The 1,409 case-parent trios are from a subset of populations pre-
viously studied by a GWAS, although not all sequenced trios were
part of the prior GWAS. Previous work on the same populations
included principal-component analysis (PCA) to explore genetic
distances. In these studies, the Europeans and European Ameri-
cans formed one cluster and the Asian individuals formed another.
Although a separate PCA of founders from the Asian trios (i.e., the
parents) appeared to separate the Philippines from other Asian
sites, the FST values were small (FST < 0.022). Given these data,
we stratified our cohort into two populations for analyses: an398 The American Journal of Human Genetics 96, 397–411, March 5Asian group combining trios from the Philippines and China
(1,034 total trios) and a European group combining all European
and European American trios (375 total trios).Selection of Targeted Regions
Thirteen high-priority regions were selected for sequencing
(Table 1), representing 6.3 Mb. Nine regions were identified by
GWASs6,9 and/or genome-wide linkage studies5,11 as primary or
secondary genome-wide significant ‘‘hits.’’ Four other regions
were selected from candidate gene studies where there was evi-
dence for some contribution of rare variants that could be best
clarified by sequencing. The coordinates for sequencing in each
of these regions were based on the location of the original
GWAS SNPs with p values < 105, LD structure in CEU or CHB/
JPT HapMap samples, annotations of regulatory regions from
the ENCODE project, and the location of candidate genes in the
immediate region. We targeted both coding and non-coding
sequence at each locus to select the boundaries of the targeted
regions, which totaled 6.3 Mb of sequence.Sequencing
Illuminamultiplexed libraries were constructed with 1 mg of native
genomic DNA according to the manufacturer’s protocol (Illumina)
with the following modifications. (1) DNA was fragmented with a
Covaris E220 DNA Sonicator (Covaris) to range in size between
100 and 400 bp. (2) Illumina adaptor-ligated library fragments
were amplified in four 50 ml PCR reactions for 18 cycles. (3)
Solid phase reversible immobilization (SPRI) bead cleanup was
used for enzymatic purification throughout the library process,
as well as final library size selection targeting 300–500 bp frag-
ments. We designed NimbleGen (Roche NimbleGen) custom
target probes to the 6.6 Mb target region and performed hybrid
capture on pools of 96 indexed samples per capture. We then
sequenced each capture pool on two lanes of Illumina HiSeq
per manufacturer’s recommendations (Illumina) for an average
of ~40 Gb per lane or ~835 Mb per sample.
Reads were mapped to the GRCh37-lite reference sequence by
BWA v.0.5.912 with the following parameters: t 4 q 4. Align-
ments weremerged and duplicatesmarked by Picard v.1.46. Germ-
line and de novo variant calling was performed with Polymutt
(v.0.11). Polymutt employs a likelihood-based framework and
provides increased sensitivity and specificity when calling de
novo variants by leveraging the parental genotype information.
We then processed variant calls by using false positive filters to
remove systematic artifacts. The first step uses bam-readcount
(v.0.4), then identifies and flags potentially artifact variants if
they fail any of the filters listed in Table S2.
Family-Relationship Testing
We evaluated familial relationships with BEAGLE’s fastIBD to
calculate identity by descent (IBD) between children and their
parents. Variant sites within the target region in at least one family
member with at least 203 coverage of the site in all individuals
were used for this fastIBD calculation. If a trio failed fastIBD,
defined as a parent-child pair sharing less than 40% of the target
region, the trio was removed from all downstream analysis.
The SNV variant calls from the final set of 1,409 trios were com-
bined into a multi-sample VCF file and all segregating sites were
genotyped in all individuals via samtools mpileup. We then
removed all sites where 50% or more individuals had a false-posi-
tive filter flag. We also removed individual variant calls with a
depth (DP) less than 7 or a genotype quality (GQ) less than 20., 2015
Table 1. Overview of Regions Sequenced and TDT Results
Region
Candidate
Gene in
Region Target Region (GRCh37) Size (kb)
Associated
SNP from
GWAS
Associated
SNP by
Sequencing psequence Population LD
GWAS 1p36 PAX7 chr1: 18,772,300–19,208,054 435.8 rs742071 rs1339062 8.88 3 104 European r2 ¼ 0.726,
D’ ¼ 0.997
1p22 ARHGAP29 chr1: 94,324,660–95,013,109 688.4 rs560426 rs560426 6.06 3 1012 Asian –
1q32 IRF6 chr1: 209,837,199–210,468,406 631.2 rs2013162 rs11119348 8.13 3 1012 Asian r2 ¼ 0.541,
D’ ¼ 0.991
8q24 chr8: 129,295,896–130,354,946 1059.1 rs987525 rs7017665 8.70 3 1011 European r2 ¼ 0.847,
D’ ¼ 0.983
10q25 VAX1 chr10: 118,421,625–119,167,424 745.8 rs7078160 rs10886036 8.08 3 109 Asian r2 ¼ 0.941,
D’ ¼ 0.999
17p13 NTN1 chr17: 8,755,114–9,266,060 510.9 rs9788972 rs9904526 3.07 3 109 Asian r2 ¼ 0.670,
D’ ¼ 0.999
17q22 NOG chr17: 54,402,837–54,957,390 554.6 rs227731 rs227727 7.32 3 108 Asian r2 ¼ 0.982,
D’ ¼ 0.991
20q12 MAFB chr20: 38,902,646–39,614,513 711.9 rs13041247 rs2865509 1.85 3 108 Asian r2 ¼ 0.752,
D’ ¼ 0.870
Linkage 9q22 FOXE1 chr9: 100,357,692–100,876,841 519.1 – rs10983654 1.31 3 105 Asian –
Candidate
Gene
4p16 MSX1 chr4: 4,825,126–4,901,385 76.3 – rs59138205 1.7 3 104 Asian –
14q22 BMP4 chr14: 54,382,690–54,445,053 62.4 – rs751399 0.01 Asian –
10q26 FGFR2 chr10: 123,096,374–123,498,771 402.4 – rs12569773 1.10 3 104 Asian –
9q22 PTCH1 chr9: 98,133,647–98,413,162 279.5 – rs61076166 2.71 3 105 European –Variants located within 75 bp of indels or dinucleotide polymor-
phisms occurring in >5% of samples were included in analyses
but were flagged as potential artifacts. The full set of indel calls
are in process and were not part of these analyses.
Variant Annotation
Variantswere annotatedwith dbSNP137 and theVariant Effect Pre-
dictor (VEP).13 The followingVEP parameterswere used:condel
bpolyphenbsift bhgnccanonical. For eachgene, the
canonical VEP annotation was used whenever possible. In the
event of multiple overlapping genes that yielded different annota-
tions, the most damaging annotation was used. Variants were also
annotated with the Combined Annotation Dependent Depletion
(CADD) tool, which integrates multiple annotations (conserva-
tions, functional genomic data [e.g., DNase hypersensitivity], and
protein scores [e.g., PolyPhen]) into a single score (C-score). We
used the scaled C-scores, which range from 1 to 99. A score greater
or equal to 10 are variants predicted to be the 10%most deleterious
substitutions genome-wide. A total of 168,129 variants were iden-
tified, only 1,059 of which were coding (Figure S1).Statistical Methods
Additional Quality Control
Prior to statistical analyses, we applied additional quality-control
criteria beyond the steps outlined above. We excluded from
analyses all SNPs with >5% missing genotypes over all trios. We
then tested for deviation from Hardy-Weinberg equilibrium
(HWE) in founders within each ancestry group (Asian and
European).
Single-Variant Analysis
We tested variants with minor allele frequency (MAF) > 1% for as-
sociation using the allelic transmission disequilibrium test (TDT).The AmeThe TDT tests for Mendelian transmission of alleles from a hetero-
zygous parent to the affected child. We implemented the test in
PLINK,14 which provides an allelic TDT assessing whether hetero-
zygous parents transmit the target allele (arbitrarily defined as the
minor allele) to the affected child at the expected 50% probability
and generating an asymptotic p value for the c2 statistic (1 degree
of freedom). To determine the significance threshold for tightly
correlated SNPs, we applied the SimpleM method15 to each
ancestry group separately. The estimated number of independent
SNPs averaged 5,200 SNPs between the Asian and European
groups. Our Bonferroni p value threshold based on this number
considered p < 13 105 to be significant, preserving a type 1 error
rate of 5%.
Conditional Analysis
For variants with significant results from the single-variant TDT
analyses, we performed a conditional analysis given the observed
genotype at the SNP with the strongest signal to determine
whether there was one signal at each region or multiple signals.
This was done in a conditional logistic regression framework
assumed by the genotypic TDT under a dominant model to maxi-
mize power. Conditioning was performed by fitting a multiple
regression model, including the most significant marker, plus
each additional individual marker in the region added sequen-
tially. We used phased haplotype data from BEAGLE to properly
account for linkage and haplotype structure in the region. We
used visual inspection of both Manhattan plots and QQ plots to
assess the presence of residual signal in this conditional analysis.
Analysis of Rare Variants
Rare variants (MAF % 1% across all founders) were analyzed by
several approaches. To select for coding variants most likely to
be functional, we restricted our analysis to rare variants with a
scaled CADD score of at least 10, corresponding to the top 10%rican Journal of Human Genetics 96, 397–411, March 5, 2015 399
of deleterious variants genome-wide. We applied rare-variant
burden tests (described below) by gene, including all variants in
a gene meeting the above criteria, and restricting the analysis to
sites annotated as ‘‘non-synonymous coding,’’ ‘‘essential splice
site,’’ ‘‘stop-gained,’’ or ‘‘stop-lost’’ by VEP. We took a similar
approach for non-coding variants, applying burden tests to re-
gions annotated as regulatory elements by ENCODE16,17 or other
similar efforts.18–20 We then took an unbiased, window-based
approach with ScanTrio to identify regions of significant non-
random transmission of rare variants.
Rare Variant ‘‘Burden’’ Tests
We performed two burden-style tests for rare variants, at the gene
level and for different classes of regulatory elements. The first
(termed T1 here) is a binomial test comparing total numbers of
transmitted and non-transmitted minor alleles for a gene/region,
i.e., rare variants within the gene or region were ‘‘collapsed’’ prior
to testing. In this analytical strategy, the observed total trans-
mitted and non-transmitted counts are tested against a null
hypothesis of equal probability of transmission and non-transmis-
sion, and p values are calculated based on a binomial distribution.
The second test (T2) uses exact probabilities calculated at each
individual locus, which are then combined to obtain a joint
statistic across a gene/region. More specifically, under the null hy-
pothesis, the probability of observing the transmitted and non-
transmitted minor allele counts, ai and bi, respectively, for the i
th
variant is obtained based on a binomial distribution:
Pi ¼ Cðai þ bi; aiÞpai ð1 pÞbi ;
where C(n,m) is a binomial function. Once variant-specific Pi
values have been obtained, they are then summarized over k var-
iants into a logarithmized joint probability score:
L ¼
Xk
i¼1
logðPiÞ;
where L reflects the joint probability of observing all k pairs of
transmission counts under the null hypothesis that none of these
k variants is associated with the trait. When ai, bi, and k are not too
large, the exact distribution of L can be obtained by enumerating
the combinations of all possible ai and bi values under the null hy-
pothesis, and calculating L for each combination with these for-
mulas. Denoting L
_
H (L1, L2,.,Lj,.LM) as an exact distribution
of L overM possible values, the p value for testing the significance
of L becomes the probability of L% Lj, which can be exactly calcu-
lated as the proportion of elements of L
_
that are less than or equal
to Lj. In the situation where M is too large to be enumerated
completely, a random sample can be drawn from L
_
(with replace-
ment) through simulation and used to approximate a p value. The
advantage of the T2 statistic over T1 is that it allows both protec-
tive and deleterious rare alleles to exist within a gene or region.
We performed these tests for various subsets of rare variants, se-
lecting based onMAF (no higher than 1% or no higher than 0.1%)
and functional annotation (coding role, condel scores from VEP or
CADD scores, and annotations for regulatory elements).
Scan-Trio
In addition to the gene/region based tests described above, we
used the Scan-Trio method to search (via sliding windows) for
sub-regions displaying over- or under-transmission of rare vari-
ants. The sliding windowswere done in twoways: first considering
either all possible windows of a given size or a number of markers,
and second considering windows of a fixed physical distance or a
fixed number of markers of overlap (to reduce the correlation in400 The American Journal of Human Genetics 96, 397–411, March 5signal between adjacent, highly overlapping windows). In brief,
this method involves calculating a likelihood ratio to test whether
the transmission rate of minor versus major alleles differs inside
the window in question, compared to the remainder of the region
under consideration (comparing a 1-parameter likelihood for the
observed data to a 2-parameter likelihood). In this way, we allow
for either over- or under-transmission of the minor allele within
a window, with the former indicating overall deleterious effect
of minor alleles in the window under consideration.
Significance was assessed by permuting transmitted and un-
transmitted haplotypes in each region, as phased with BEAGLE,
and then recalculating the Scan-Trio likelihood for each window
on each permuted dataset. This approach both preserves the
correlation structure between neighboring markers (i.e., the LD
between nearby variants) because haplotypes are the units of per-
mutation and allows for comparative assessment of neighboring
windows with different MAFs, because significance is assessed
for the same window across all permutations, thus fixing the
MAFs for any given window. To identify windows showing more
significant signal than was expected by chance alone, we em-
ployed QQ plots and looked for outliers from the expected distri-
bution under the null hypothesis.
Sanger Sequencing of De Novo Mutations
We designed primers covering one or more de novo mutations
with Primer3 for 82 of the 123 high-confidence de novomutations
identified in this study that were also absent from dbSNP137.
The remaining de novo mutations were in highly repetitive
sequence where unique PCR products could not be generated or
for trios where additional samples were unavailable. PCR products
for all members of the trio were sequenced on an ABI 3730XL
(Functional Biosciences). Chromatograms were then transferred
to a Unix workstation, base-called with PHRED (v.0.961028),
assembled with PHRAP (v.0.960731), scanned by POLYPHRED
(v.0.970312), and visualized with the CONSED program (v.4.0).Follow-up Functional Studies
Zebrafish Husbandry
A pet store strain of zebrafish was maintained by standard
methods except parental fish were housed at room temperature
overnight prior to breeding.21 Embryos were raised at 28.5C.
The ethical use of animals for research was approved by the Uni-
versity of Iowa Institutional Animal Care and Use Committee.
Zebrafish Enhancer Screen
Potential regulatory elements (i.e., FGFR2 þ254 kb [GRCh37,
chr10: 123,099,588–123,100,426]; NOG þ87 kb [GRCh37, chr17:
54,755,547–54,757,398]; and NOG þ105 kb [GRCh37, chr17:
54,776,294–54,777,215]) were PCR amplified from human
genomic DNA, cloned into the Gateway (Invitrogen) pENTR/
D-TOPO vector, and transferred to the zebrafish enhancer detec-
tion vector (ZED).22 In this dual reporter vector, one cassette is
comprised of Gateway recombination sites, a minimal gata2a pro-
moter, and the gene encoding enhanced green fluorescent protein
(eGFP). The second cassette, which serves to report on the degree
of mosaicism and also an internal control of transformation effi-
ciency, is the cardiac-actin promoter upstream of dsRed2 gene.
The ZED vector also contains Tol2 recombination sites bracketing
the entire construct to facilitate Tol2-mediated integration of the
expression construct into the zebrafish genome, thus reducing
cell mosaicism within the injected embryos. All plasmid con-
structs were sequenced and the sequence results were aligned
onto the human genome with the UCSC tool BLAT23 to ensure, 2015
fidelity of these steps. No other variants were detected within the
plasmids. tol2mRNAwas transcribed from the plasmid pKJ-Tol2.24
ZED constructs (25–30 ng/ml) were injected along with the tol2
mRNA (20–30 ng/ml) into 100–200 zebrafish embryos at the
1-cell stage. The developing embryos were screened at 24, 48,
72, and 96 hr after fertilization for eGFP expression. A consistent
pattern of expression in a minimum of 10% of injected fish was
the criterion for tissue-specific enhancer activity, which is gener-
ally sufficient to predict the expression pattern present in F1,
non-mosaic transgenic lines.25 The use of recombinant DNA
was approved by University of Iowa Institutional Biosafety
Committee.
Photography
Zebrafish embryos were photographed in bright field, epi-fluores-
cent illumination, or differential interference contrast imaging
on a Leica DMRA2 compound microscope with a color 12 bit
‘‘QIClick’’ camera (Qimaging).
Electrophoretic Mobility Shift Assays
A full-length human PAX7 cDNA was acquired from ATCC. The
p.Ala259Val substitution was introduced into it by PCR-mediated
mutagenesis.26 cDNA encoding wild-type and p.Ala259Val PAX7
were shuttled into the CS2þ vector and the corresponding pro-
teins were generated in vitro with a TNT kit (Promega). The prod-
ucts of the protein synthesis reactions were separated by gel
electrophoresed NuPAGE 4%–12% Bis-Tris Gel (Life Technologies)
and stained with coomassie blue (Bio-Rad). EMSA were carried out
according tomethods of Carey et al.27 In brief, PAX7 proteins were
incubated with 4 pmol double stranded oligonucleotide, contain-
ing the Pax7 binding site present in the id3 promoter,28 and end
labeled with infrared tag (sequence of probe: 50-GCTTCACCG
CAATTAATGTGCATAGAGTGTGGTCACAAGATAATTCCTGA-30).
Protein and probe were incubated for 20 min at room temperature
in LI-COR binding buffer, 25 mMDTT/2.5% Tween20, poly(dI-dC),
sheared salmon-sperm DNA, and 50% glycerol (LI-COR). In
competition experiments, an unlabeled version of the same oligo-
nucleotide, at 10- or 100-fold excess, was added to the protein
20 min prior to addition of the labeled probe. Reaction products
were electrophoresed on 4.5% poly acrylamide gel and imaged
on the Odyssey Infrared Imaging System (LI-COR).
Luciferase Reporter Constructs, Transfections, and Luciferase Assays
For tests of the PAX7 de novomutation, a synthetic PAX7-sensitive
enhancer was generated by synthesizing an oligonucleotide con-
taining four replicates of the PAX7 binding site found in the id3
promoter (sequence) and engineering it into pTol2-cFos-FLuc.
The same FGFR2 þ254 construct used in the zebrafish studies
(GRCh37, chr10: 123,099,588–123,100,426) was modified by
PCR-mediated mutagenesis to test the de novo mutation at
GRCh37, chr10: 123,099,960. Both variants of this element
were engineered into pTol2-cFos-FLuc. This plasmid, which we
generated from one described previously, contains Tol2 recombi-
nation sites, a Gateway cloning site, the c-fos minimal promoter,
and the gene encoding firefly luciferase. Similarly constructs
of the NOG þ105 kb element (GRCh37, chr17: 54,776,294–
54,777,215), containing either the major allele of rs227727 (i.e.,
A) or the minor allele of rs227727 (i.e., T), was engineered into
pTol2-cFos-FLuc. For tests of the PAX7 de novo mutation, HeLa
cells were used, and CS2þ plasmids encoding either wild-type or
the p.Ala259Val substitution were co-transfected with PAX7-sensi-
tive reporter described above. For tests of the FGFR2 and NOG
non-coding elements, transient transfections were performed
with Lipofectamine 3000 (Roche) into GMSM-K (human embry-
onic oral epithelial cells) or MC3T3-E1 (murine osteoblastic cells).The AmeFor each construct, three independent transfections were per-
formed with Renilla luciferase (pTol2-cFos-RLuc) co-transfection,
as a control for transfection efficiency. The Dual-Luciferase
Reporter Assay System (Promega) and a luminometer were used
to measure luciferase activity in cell lysates. All quantified results
are presented as mean 5 SEM. Three luciferase measurements
were made on each of three independent biological replicates. A
two-tailed unpaired Student’s t test was used to determine statisti-
cal significance.
Cell Culture
GMSM-K human embryonic oral epithelial cell line (a kind
gift from Dr. Daniel Grenier)29 was maintained in keratinocyte
serum-free medium (Life Technologies) supplemented with EGF
1-53 and bovine pituitary extract (Life Technologies). MC3T3-E1
(ATCC) murine osteoblastic cells were maintained in MEM-alpha
(Life Technologies) supplemented with 10% fetal bovine serum
(Life Technologies). HeLa cells were maintained in Dulbecco’s
Modified Eagle’s Medium (Life Technologies) supplemented
with 10% fetal bovine serum. All cells were incubated at 37C
and 5% CO2.
Murine Crosses
We crossed mature C57BL/6J mice. Presence of a copulation
plug on the following morning was designated as E0.5. Animal
use protocols were approved by the Institutional Animal Care
and Use Committees at Michigan State University.
Immunostaining
Pregnant dams were sacrificed at E13.5. Harvested embryos were
fixed, embedded in paraffin, sectioned, and immunostained
as described previously.30 Primary antibodies were incubated over-
night at 4C and includedNOG (Ab16054, Abcam), NTN1 (PC364,
Oncogene), KRT6 (Covance, PRB-169P), p63 (Santa Cruz, 4A4,
SC-8431), and IRF6 (kindly provided by Dr. Akira Kinoshita, Uni-
versity of Nagasaki). Secondary antibodies were incubated at
room temperature for 1.5 hr and included a goat anti-rabbit
(Molecular Probes, A21429) and a goat anti-mouse (Molecular
Probes, A11029) antibody. Nuclei were counter-stained with
DAPI (Invitrogen, D3571). We mounted all slides in ProLong
Gold Antifade Reagent (Invitrogen, P36930). Imaging was per-
formed as described previously.30
Mapping of Putative Transcription Factor Binding Sites
TRANSFAC 7.0, Patch 1.0, and JASPAR software were used to pre-
dict putative transcription factor binding sites within NOG þ105
kb and FGFR2 þ254 kb elements. We used databases of mamma-
lian and vertebrate transcription factor binding motifs for predic-
tion of putative binding sites as previously described.31 The
binding sites were filtered based on the number of nucleotides,
conservation of each nucleotide based on the consensus motif,
and relevance of transcription factor.Results
Our sequencing and analytical pipelines, depicted in
Figure 1, identified potential functional variants that
were de novo, common (minor allele frequency [MAF] >
1%), and rare (MAF% 1%) variants in the 1,409 trios pass-
ing quality-control procedures (Table S1).De Novo Mutations
Although de novo mutations cannot contribute directly to
GWAS signals, they might help pinpoint the location ofrican Journal of Human Genetics 96, 397–411, March 5, 2015 401
Figure 1. Diagram of Analyses Performed
Variants were categorized by allele frequency (common variants had MAF > 1%; rare variants had MAF% 1%). Statistical analyses were
performed and selected regions/variants were prioritized for functional analyses in vivo or in vitro.functional common variants. We identified 123 unre-
ported de novo mutations considered as such because
they were not seen in parents and were absent from
dbSNP137. One of these 123 mutations occurred
in a splice-site of IRF6 (RefSeq accession number
NM_006147.3; c.1060þ1G>T [p.?]). IRF6 mutations are
known to cause Van der Woude syndrome (MIM
119300), which can appear as a phenocopy of NSCL/P
in ~15% of cases. Because we could not reexamine the
affected child for lip pits (a defining feature of Van der
Woude syndrome), this trio was excluded from further
analysis in the current study. We attempted validation
by Sanger sequencing for 82 de novo mutations where
primers could be uniquely designed and where sufficient
DNA was available; of these, 66 (80%) were confirmed
(Table S3). Among these, three (3.6%) were missense muta-
tions occurring in protein-coding genes (ABCA4 [MIM
601691], PIK3R5 [MIM 611397], PAX7 [MIM 167410]).
The ABCA4 mutation was later identified in the NHLBI
Exome Sequencing Project cohort and deposited in
dbSNP138 (rs369860406). The PIK3R5 mutation (RefSeq
NM_014308.3; c.1085C>T [p.Ala362Val]) appeared to be
mosaic because the alternate allele was found in only
36% of reads (Figure S2). We discuss the PAX7 mutation
in detail below. The majority (63, 95%) fell in non-coding
intergenic or intronic DNA. We annotated these non-cod-402 The American Journal of Human Genetics 96, 397–411, March 5ing mutations for potential functional consequence using
active chromatin signatures from the ENCODE project as
well as recently published catalogs of craniofacial and neu-
ral crest enhancer candidates.18,19 Eleven (16.6%) of the
mutations occurred within regulatory elements annotated
by Ensembl’s Variant Effect Predictor (VEP) and are there-
fore candidates to be functional. Of these non-coding mu-
tations, one at the FGFR2 (MIM 176943) locus was chosen
for functional analysis described below because it resides
within a cranial neural crest enhancer candidate. In sum-
mary, direct sequencing of GWAS intervals led to identifi-
cation of several de novo mutations within functionally
annotated coding and non-coding regions.
Common Variants
To identify functional common variants, we used an allelic
transmission disequilibrium test, performed conditional
analysis to identify regions with multiple independent
signals, annotated variants with multiple metrics, and
performed follow-up functional studies. Almost all of the
GWAS regions except PAX7 showed evidence of associa-
tionwith p values< 105 (Table 1; Tables S4 and S5; Figures
S3–S10). In general, our results replicated the associations
from GWASs with the variant yielding the lowest p value
being either the same SNP identified by GWAS or in high
LD with the reported GWAS SNP (Tables 1, S4, and S5)., 2015
Stratified analysis of the European and Asian populations
showed much greater significance in the Asian trios.
Only the 8q24 region showed significant associations in
the European trios (rs7017665, p ¼ 8.7 3 1011). These
associations were largely unchanged when the two popula-
tions were combined (Table S6). In contrast to the GWAS
regions, we did not observe any significant associations
near MSX1 (MIM 142983), FGFR2, BMP4 (MIM 112262),
PTCH1 (MIM 601309), or FOXE1 (MIM 602617), all of
which were selected from candidate gene studies and
have not shown significance in GWASs (Figures S11–
S15). Based on the conditional analysis performed, only
ARHGAP29 (MIM 610496) showed evidence for multiple
independent signals, suggesting more than one common,
functional variant at this locus (Figure S16). In summary,
dense sequencing of GWAS regions identified additional
common variants associated with NSCL/P beyond those
implicated by previous GWASs.
Rare Variants
The common variants associated with NSCL/P account for
only a fraction of disease heritability. The genes within
GWAS regions are logical candidates to harbor rare vari-
ants, which are independent of the GWAS signal and
might contribute to the risk of disease. Counts of rare cod-
ing variants per gene are listed in Table S7. To identify rare
variant signals, we carried out burden tests on sets of vari-
ants based on various annotations (i.e., genes, regulatory
elements; see Subjects and Methods). Neither gene nor
regulatory element burden tests showed significant non-
random transmission of rare variants after correction for
multiple testing. In the ScanTrio analysis, by using an
unbiased window-based approach, we experimented with
different window sizes and overlaps and found signals of
interest for 2 of the 13 regions (NOG [MIM 602991] and
NTN1 [MIM 601694], discussed in detail below).
From the results described briefly above, there were
multiple regions with de novo, rare, or common variants
worthy of follow-up. Comprehensive studies of these re-
gions and variants are ongoing. Here we selected a few of
the most promising regions for additional experiments
by using in vitro and in vivo model systems. We selected
two de novo mutations and a common variant for func-
tional assessment. Below, we present five genes (and
regions near those genes) where our statistical and/or func-
tional analyses advanced our knowledge of the genetic
etiology of CL/P.
PAX7 at 1p36
The PAX7 region was a second-tier GWAS hit,6 later
confirmed by replication32 and meta-analysis.10 Although
we were unable to replicate this common variant associa-
tion, we identified a non-synonymous de novo muta-
tion in PAX7 (Figure 2A). This mutation (RefSeq
NM_002584.2; c.766C>T) resulted in a substitution,
p.Ala259Val, at a highly conserved residue in the DNA-
binding domain (Figure 2B) and is predicted to beThe Amedamaging under multiple bioinformatic algorithms (Poly-
phen, SIFT, CADD). Because of its location in the DNA
binding domain, we hypothesized that this mutation
would disrupt the ability of PAX7 to bind DNA. To test
this notion we carried out electrophoretic mobility shift as-
says using protein synthesized in vitro and an oligonucle-
otide probe matching PAX7-binding regulatory sequence
upstream of ID3.28 In this assay, wild-type (encoding
Ala259) PAX7 binds the probe more than the p.Ala259Val
substitution (Figure 2C). We next carried out quantitative
reporter assays in HeLa cells transfected with a luciferase
reporter vector containing four copies of the PAX7 binding
site. Co-transfection of a plasmid encoding wild-type
PAX7 drove significantly higher expression levels relative
to a plasmid encoding the p.Ala259Val substitution
(Figure 2D). PAX7 is involved in neural crest induction
and is expressed in cranial neural crest cells, and mice lack-
ing Pax7 have malformations of the nasal and maxillary
structures.33 Collectively, these results indicate that this
de novo mutation disrupted PAX7 function and might
contribute to CLP pathogenesis in this individual. Further-
more, they also imply that the GWAS signal in this region
reflects a variant that alters the expression level or function
of PAX7 rather than another gene in the region.
ARHGAP29 at 1p22
The 1p22 locus was selected for sequencing from GWASs.6
Our TDT results replicated the results from GWASs exactly;
the peak association signal was located within an intron
of ABCA4 (rs560426, pAsian ¼ 6.06 3 1012). We then
extended these results by conditioning on rs560426,
revealing a second signal (rs77179923, pAsian ¼ 4.16 3
105). This independent signal was located in a linkage
disequilibrium block adjacent to the one containing
rs560426 (Figure S16). Both peaks are located within in-
trons of ABCA4, which contain regulatory elements and
at least one craniofacial enhancer.18 However, ABCA4 is
not expressed in the developing lip or palate34 and muta-
tions are associated with a number of ocular disorders.35
By contrast, the neighboring gene, ARHGAP29, is ex-
pressed in the developing lip and palate in murine em-
bryos.34 Moreover, previous sequencing of ARHGAP29
identified multiple rare variants, including a nonsense
variant and a frameshift mutation, in families with
NSCL/P.34 In the present study, we identified a number
of rare variants in ARHGAP29, including 17 previously
unreported variants that in aggregate were not signifi-
cantly over-transmitted to affected offspring. However,
four nonsense variants (RefSeq NM_004815.3; c.976A>T
[p.Lys326*]; RefSeq NM_004815.3; c.1939C>T [p.Arg647*];
RefSeq NM_004815.3; c.2367G>A [p.Trp789*]; RefSeq
NM_004815.3; c.3118G>T [p.Gly1040*]) were transmitted
to the affected children (we previously reported the family
with the c.976A>T (p.Lys326*), variant34). Nonsense vari-
ants in ARHGAP29 have never been reported by either the
1000 Genomes Project or the NHLBI Exome Sequencing
Project, which cumulatively have sequenced more thanrican Journal of Human Genetics 96, 397–411, March 5, 2015 403
Figure 2. A De Novo Missense Mutation
in PAX7 Disrupts DNA Binding
(A) Aligned sequence reads of the affected
child, father, and mother showing
the de novo PAX7 mutation, encoding
p.Ala259Val, using the Integrative Geno-
mics Viewer.
(B) Schematic of the PAX7 protein indi-
cating the location of this mutation in the
homeo-domain. Also shown is a 3D struc-
tural representation of the homeo-domain
of PAX3 dimerized (dark blue and light
blue ribbon structures) and in complex
with DNA (gray stick representation) (Pro-
tein Data Bank ID 3CMY). PAX3 is homol-
ogous to PAX7. The position of Ala259 is
marked in red and indicated by red arrows.
(C) Electrophoretic mobility shift assay
using synthesized PAX7 protein. In vitro
synthesized PAX7 proteins, driven by
expression of the wild-type or mutant
alleles as indicated, were incubated with a
labeled probe containing paired and ho-
meo-domain binding sites, based on ID3,
or an unlabeled version of the same
probes as indicated. At every dose of the
competing unlabeled probe, the intensity
of the band of protein-bound probe (arrow)
is fainter in the reaction containing the
mutant protein than in the one containing
wild-type protein.
(D) Luciferase reporter assay. Cells were
transfected with plasmids, encoding wild-
type or mutant PAX7 as indicated, a
PAX7-sensitive firefly luciferase reporter
vector, and a constitutively expressed re-
nilla luciferase reporter. Luciferase signal
is the ratio of firefly and renilla luciferase
measurements. Error bars: standard devia-
tion from three replicate experiments.7,000 individuals. Together these observations indicate
that ARHGAP29 is the gene underlying the pathogenesis
of NSCL/P at this locus.
FGFR2 at 10q26
The FGFR2 locus was selected for sequencing for several
reasons: FGFR2 plays a role in craniofacial develop-
ment,36 mutations in FGFR2 cause two craniosynostosis
syndromes that include orofacial clefting,37,38 and rare
coding variants and deletions in FGFR2 were previously
found in cases with nonsyndromic clefts.39,40 Although
neither common variants nor rare coding variants are
over-transmitted to cases in our analysis, we detected
a de novo mutation within non-coding DNA that pos-
sesses chromatin marks indicative of an active neural
crest enhancer17,41 (Figure 3A). This mutation (RefSeq
NC_000010.10; g.123099960G>A) is located 254.6 kb
downstream of the FGFR2 transcription start site, herein
referred to as the þ254 kb element, and disrupts predicted404 The American Journal of Human Genetics 96, 397–411, March 5, 2015transcription factor binding sites
(Figure S17). In transient transgenic
reporter studies in zebrafish embryos,we demonstrated that the reference allele of the human
þ254 kb element has enhancer activity in the neural keel
(Figure 3C), brain (Figure 3D), and delaminating neural
crest (Figure S18), consistent with expression of Fgfr2 in
brain and cranial neural folds in mice42 and zebrafish.
In parallel experiments, the de novo mutation revealed
enhancer activity in fewer embryos (3/83) than the refer-
ence allele (41/82; p ¼ 1.70 3 1012) (Figures 3E and
S18). We also tested the þ254 kb element in a mesen-
chymal cell line in vitro and discovered that the de novo
mutation had significantly lower activity than the wild-
type allele (Figure 3E). These findings suggest this de
novo mutation adversely affects a neural crest enhancer
that, presumably, regulates FGFR2 expression.
NTN1 at 17p13
In an earlier GWAS, the 17p13 locus was considered a sec-
ond-tier hit because it did not quite reach genome-wide
significance.6 However, we found that the minor alleles
Figure 3. A De Novo Mutation in an Enhancer 254 kb Downstream of FGFR2 Disrupts Enhancer Activity
(A) Aligned sequence reads of the affected child, father, and mother showing the de novo mutation (GRCh37: chr10: 123099960G>A).
(B) UCSC Genome Browser view of the þ254 kb element. The de novo mutation falls within a human neural crest enhancer candidate
defined by chromatin marks.
(C and D) Transiently transgenic embryos injected with a reporter construct containing the wild-type form of the FGFR2 þ254 kb
element, a minimal promoter, and Gfp and imaged under epi-fluorescent illumination.
(C) Dorsal view of a 12 hr postfertilization (hpf) animal. Gfp signal is evident in the brain. Scale bars represent 20 mm.
(D) Lateral view of the head of 48 hpf animal. Gfp signal is evident in the forebrain, midrain, and hindbrain.
(E) Bar chart showing number of animals with Gfp signal in brain and RFP expression in the trunk, among animals injected with Gfp
reporter vector containing wild-type and mutant forms of the FGFR2 þ254 kb element.
(F) Quantitative reporter assays in vitro comparing wild-type and de novo mutant allele of the FGFR2 þ254 kb element. MC3T3 cells
were transfected with firefly luciferase vector containing wild-type or de novo mutant variants of the FGFR2 þ254 kb element, and a
constitutively expressed renilla luciferase reporter. Luciferase signal is the ratio of firefly and renilla luciferase measurements.
Error bars indicate standard deviation from three replicate experiments.of multiple markers within one LD block conferred risk at
genome-wide significance (e.g., rs9904526, pAsian ¼ 3.07 3
109) (Figure 4A). These markers are located between
PIK3R5 and NTN1. Although we cannot exclude PIK3R5
(or other genes in this region), follow-up studies on
PIK3R5 alleles were not performed here for the following
reasons. First, our ScanTrio analysis identified a protective
signal in the window chr17: 8,812,274–8,830,333 (located
within PIK3R5) containing 18 informative markers and
showed a significant transmission of 6 minor alleles
compared to 32 major alleles (permutation p < 104)
across all heterozygous rare variant genotypes in the
window (Table S8). Among these variants were multiple
annotations for coding variants in PIK3R5. Second, a
homozygous missense mutation in PIK3R5 was reported
in a consanguineous family with ataxia oculomotor
apraxia-3 (MIM 615217), an autosomal-recessive disorder
that does not include an orofacial phenotype.43 Finally,
mice that lack Pik3r5 are viable, whereas mice with an
orofacial cleft die during the perinatal period because
they cannot suckle.44The AmeIn contrast, NTN1 remains a strong candidate gene. The
associated common SNPs at 17p13 clustered near the tran-
scription start site ofNTN1. To date, nomutations inNTN1
have been associated with any phenotype in humans.
Moreover, mice that lack Ntn1 lack the white spot of
milk in the stomach and die during the perinatal period,
consistent with a cleft palate phenotype.45 To confirm
that NTN1 is localized to the palate, we performed anti-
NTN1 immunofluorescence on murine embryos (E13.5).
Palatal shelves are composed of two epithelial layers, the
periderm and the basal layer, along with underlying
mesenchyme. We marked these tissue compartments by
processing samples to reveal characteristic immunoreac-
tivity: anti-KRT6 to label periderm (Figures 4B and 4C),
anti-IRF6 to label both layers or oral epithelium (Figures
4D and 4E), and anti-p63 to label nuclei of the basal epithe-
lial cells (Figures 4F and 4G). We observed high-level anti-
NTN1 immunoreactivity in the mesenchyme, especially
along the basement membrane of the palatal shelves (Fig-
ures 4F and 4G), and at highest levels along the presump-
tive medial edges and oral sides of the palatal shelves. Thisrican Journal of Human Genetics 96, 397–411, March 5, 2015 405
Figure 4. Association and Immunostaining of NTN1
(A) Regional association plot for TDTof common variants at 17p13 in 1,034 Asian trios. The SNP with the smallest p value (rs9904526) is
marked by the solid red triangle. The direction of the triangles reflects the direction of association with the minor allele. Shown below
the association plot are locations of genes in the region and linkage disequilibrium (measured as r2).
(B–G) Immunostaining of coronally sectioned wild-type murine heads at E13.5. DAPI counterstains nuclei in all sections (blue). Right
images (C, E, G) are magnifications or left images (B, D, F).
(B and C) KRT6 marks oral periderm (arrow) in the palate, tongue, and mandible.
(D and E) IRF6 marks the oral epithelium, including both the periderm and basal cell layer.
(F and G) NTN1 is localized to both the mesenchyme and basement membrane (arrowhead).
Scale bars represent 2mm (B, D, F) or 50 mm (C, E, G). Labeled oral structures are the tongue (t), maxilla (mx), mandible (mn), and palatal
shelves (p).pattern is interesting because NTN1 was previously shown
to regulate cell migration during embryogenesis45–47 and
in other developmental processes,48–50 and breakdown of
the basement membrane along the medial edge and inva-
sion by mesenchymal cells is a critical step in palatal
fusion.
NOG at 17q22
The 17q22 region achieved genome-wide significance in a
meta-analysis of the Mangold et al.9 and Beaty et al.6
genome-wide scans.10 In this region, we identified multi-
ple SNPs reaching genome-wide significance with greatest
significance detected at rs227727 (pAsian ¼ 7.3 3 108),
about 105 kb downstream of the NOG transcriptional start
site (Figure 5A). This SNP was in complete linkage disequi-
librium with rs227731, the SNP with most significant asso-
ciation in the GWAS mentioned above. Within 1.5 kb of
this common variant signal, the ScanTrio analysis of rare
variants showed some evidence (permutation p < 103)
of combined significance of rare variants. The most signif-
icant window occurred between chr17: 54,770,168 and406 The American Journal of Human Genetics 96, 397–411, March 554,771,787 and encompasses five informative markers,
which showed overall transmission of eight minor alleles
compared to no major alleles. A summary of annotation
data for the variants in these regions is included in
Table S8 and their location is illustrated in Figure 5B.
Prior work showed that transcripts of Nog, encoding a
BMP antagonist, were expressed primarily in the epithe-
lium during palatal development.51 To further define the
expression pattern, we processed mouse embryos to reveal
anti-NOG immunoreactivity, again using anti-Tp63 and
anti-IRF6 immunoreactivity as markers of different layers.
We observed that Nog protein localized primarily to the
palatal epithelium, in both basal and periderm layers,
but also was detectable in mesenchyme (Figures 5C and
5D). These results are consistent with a mechanism
affecting epithelial development, but because NOG is a
secreted ligand, non-cell-autonomous functions are also
possible. For example, overexpression of Nog in palatal
mesenchyme caused a cell-autonomous failure of palatal
shelf growth and also a non-cell-autonomous loss of
epithelium.51, 2015
Figure 5. rs227727 Is a Functional Variant Associated with NSCL/P
(A) Regional association plot for TDTof common variants at 17q22. The SNP with the smallest p value (rs227727) is marked by the solid
red triangle. The direction of the triangles reflects the direction of association with the minor allele. Shown below is the linkage disequi-
librium in the region (measured as r2).
(B) UCSC Genome Browser view of the LD block containing the most significant SNPs. In order, the tracks shown are (1) the locations of
SNPs with p< 13 105, (2) the rare variants in the significant window from ScanTrio (in purple), (3) chromatin state segmentation tracks
from ENCODE (enhancers are indicated by red, orange, and yellow bars), (4) DNase I hypersensitivity clusters from ENCODE, and (5)
transcription factor ChIP-seq from ENCODE. The þ87 kb and þ105 kb regulatory elements are marked with green boxes.
(C and D) NOG is present in the periderm, basal cell layer, and underlying mesenchyme. Scale bars represent 2 mm (C) or 50 mm (D).
Labeled oral structures are the tongue (t), maxilla (mx), mandible (mn), and palatal shelves (p).
(E and F) Transient transgenic embryos injected with a reporter construct containing the wild-type form of the NOG þ87 kb element, a
minimal promoter, and Gfp and imaged under epi-fluorescent illumination. GFP signal is evident in the epithelium of the 24 hpf
embryos. Scale bar represents 10 mm. Surface epithelium (E) and zoomed-in view (F), showing classic hexagonal cell shape of a squamous
cell epithelial cell, confirming that GFP is labeling the surface epithelium.
(G) Luciferase assay comparing the activity of NOG þ105 kb element with wild-type or risk allele. GMSM-K cells were co-transfected
firefly luciferase reporter vector with NOG þ105 kb element with wild-type or risk allele, or tandem-engineered NOG þ105 kb and
þ87 kb element, and a constitutively expressed renilla luciferase reporter. Luciferase signal is the ratio of firefly and renilla luciferase
measurements. Error bars represent standard deviation from three replicate experiments.Within the linkage disequilibrium block containing
rs227727, there are two regions that are strong candidates
to be active enhancers in a number of cell lines, based on
the specificpatternof chromatinmarks52 (Figure 5B).Given
the chromatin signature and the presence of binding sites
for craniofacial transcription factors TFAP2A and c-MYC,
we tested them for evidence of regulatory activity in vivo
and in vitro. One element, located þ87 kb from the NOG
translation start site, is an epithelial enhancer in zebrafish
(Figures 5E and 5F). The second element, atþ105 kb, lackedThe Ameconsistent enhancer activity in transient transgenic
zebrafish assays. However, this element had low-level
enhancer activity in vitro in human fetal oral epithelial
cells (GMSM-K) (Figure 5G) and murine osteoblastic cells
(MC3T3) (Figure S19). Interestingly, the enhancer activity
of the þ105 kb element in both cell types was significantly
lower with theNSCL/P-associated allele of rs227727 (i.e., T)
than with the unassociated allele (i.e., A) (Figures 5G
and S18). Because of the low-level activity of the þ105 kb
element in GMSM-K cells, we engineered reporterrican Journal of Human Genetics 96, 397–411, March 5, 2015 407
constructs containing theþ87 kb andþ105 kb elements in
tandem. The combined activity of these two elements is at
least additive and the construct containing the rs227727
risk allele again had significantly decreased activity
(Figure 5G). Of note, the disease-associated variant disrupts
predicted binding sites for MEF2C and CDX2 and creates
binding sites for several transcription factors, including re-
pressorsGFI1 andNKX2.5, but it is unknownwhich specific
binding events are altered by this allele (Figure S17). In sum-
mary, we have identified a common variant, rs227727, in
100% linkage disequilibriumwith themost-strongly associ-
ated SNP identified in GWAS (which now appears to be an
index SNP) that alters the function of an enhancer. This is
one of few examples of a common non-coding variant
that is strongly associated with a structural birth defect
where there is evidence that it is functional.Discussion
To identify candidate variants that might be causal for
non-syndromic cleft lip with or without cleft palate
(NSCL/P), we carried out a targeted sequencing study of
NSCL/P GWAS regions. After sequencing 1,409 case-parent
trios from multiple Asian and European populations, we
identified many candidate functional variants and carried
out preliminary functional analyses on three especially
strong candidates.
We identified de novo mutations in 8% of sequenced
probands and further showed that two of them, one cod-
ing and one non-coding, have functional effects in our
model systems. De novo mutations play a prominent
role in several other complex disorders, including autism,
intellectual disability, and schizophrenia.53,54 Given the
small number of coding de novo mutations identified in
this study and in earlier, smaller-scale studies,39,55 it does
not appear that coding de novo mutations play a signifi-
cant role in disease burden of NSCL/P. However, the contri-
bution of de novo mutations to NSCL/P might be higher
than observed here because many of the trios (40%)
selected for this study came from larger multiplex pedi-
grees or have a reported family history of clefting; the dis-
ease in such families is unlikely to be caused by a single de
novo mutation. However, even in multiplex families it is
possible that de novo mutations comprise some fraction
of the alleles determining the disease liability in each indi-
vidual. The PAX7 de novo mutation is only the third re-
ported coding de novo point mutation in an individual
with NSCL/P. Previous point mutations were described in
TP6355 and FGF8.39 Of the non-coding de novo variants,
we chose one located downstream of FGFR2 as the most
promising candidate and demonstrated its role in disrupt-
ing activity of a neural crest enhancer. Future investiga-
tions of the remaining de novo mutations from this study
are likely to reveal additional functional effects.
About half of the heritability for NSCL/P has not been
ascribed to any gene or locus, suggesting a major contribu-408 The American Journal of Human Genetics 96, 397–411, March 5tion from rare variants. Therefore it was unexpected that
we observed a statistically significant over-transmission
of rare variants in only 2 of 13 regions analyzed (in non-
coding DNA near NOG and NTN1), notably not detecting
any signal in four regions selected for sequencing based
on reported contribution of rare variants (i.e., BMP4,
FGFR2, MSX1, and PTCH1). Missense and nonsense muta-
tions in BMP4 were associated with a combination of overt
cleft lip, microform clefts, and discontinuities in the supe-
rior orbicularis oris muscle.56 However, the present study
had insufficient phenotypic data to replicate this earlier
result because only a small number of families in this study
have undergone assessment for orbicularis oris discontinu-
ities. Previous work on the FGF family of genes identified
several interesting variants in FGFR2 suggested to be
damaging via structural protein modeling,39 and there is
evidence that FGFR2 is associated with nonsyndromic
clefting.57 Although we did not identify a significant
over-transmission of rare variants in FGFR2, individual
variants could still prove to be functional upon further
investigation. Similar conclusions pertain to MSX158 and
PTCH1,59 which both contain potentially damaging rare
variants in our dataset, but did not show overall excess
transmission of rare variants. Importantly, because func-
tional and non-functional variants cannot be readily dis-
cerned from one another, our burden tests include both
and therefore have reduced power (as seen in simula-
tions60). Systematic testing of variants to identify the sub-
set of functional variants was previously successful in other
studies61 and might be required with NSCL/P, because bio-
informatics tools for predicting protein function have low
accuracy. We conclude that identifying causal rare variants
will require additional extensive sequencing of regions
identified by GWASs or containing candidate genes in
larger sample sizes and would benefit from improved algo-
rithms for recognizing functional variants in coding and
non-coding sequence.
Our TDT analyses of common variants identified strong
associations in multiple regions with NSCL/P in our Asian
samples, but only in a single region, 8q24, in our European
trios. This was unexpected because previous candidate
gene studies and GWASs identified strong associations
at IRF6,3,4 FOXE1,11 NOG,9 and VAX19 (MIM 604294) in
European populations. The number of European trios
sequenced might have contributed to this, because smaller
numbers might create a lack of power to detect significant
associations. In the present study, combining the Asian
and European trios resulted in smaller p values for the asso-
ciations with NOG and VAX1, indicating an additional
contribution by the European trios (Table S6). However,
for the IRF6 and FOXE1 regions, the p values were largely
unchanged in the combined analysis (Tables S6). Note
that in previous studies,3,4,32,62 the significant results
were driven by Northern European populations from
Denmark and Norway. In contrast, our European trios are
a heterogeneous group of Europeans and European Amer-
icans with self-reported white ancestry. Insufficient power, 2015
might also have contributed to the lack of association at
PAX7, which did not reach formal genome-wide signifi-
cance by GWAS until combined in a meta-analysis of the
two largest studies.10
Nonetheless, our analyses of common variants and the
surrounding regions have yielded several insights that
will aid identification of pathogenic variants for NSCL/P.
First, we have demonstrated how the genetic architecture
of most of the sequenced GWAS regions is comparatively
simple, reflected by only one common variant signal in
each region. The only exception was the 1p22 region,
where we identified two independent signals in the introns
of ABCA4. Second, we identified NTN1 as the gene likely to
underlie the association at 17p13. Finally, we propose that
rs227727 might itself be a functional variant at the 17q22
(NOG) locus and support this claim with experimental
evidence. Previously, the only common variant proposed
to be functional in NSCL/P was rs642961, located in an
enhancer element upstream of IRF6.4 In addition to
rs227727, we identified numerous common variants in
other regions that might demonstrate functional capabil-
ities in further studies.
Here we demonstrated that targeted sequencing of
large intervals surrounding GWAS regions is an effective
approach for identifying functional rare and common var-
iants in both coding and non-coding regions. In aggregate,
our analyses highlight the important role of non-coding
regulatory elements and suggest that disruption of these
regions by genetic variants is a critical aspect of the patho-
genesis of NSCL/P. It will be important to replicate these
results in other independent populations and to sequence
additional cohorts that might have unique risk alleles, for
example Hispanics, Africans, and Native Americans. We
conclude that sequencing of all GWAS-implicated regions
in a wide range of populations, together with functional
analyses, will be necessary to fully understand the role of
these genes/regions in the etiology of NSCL/P.Accession Numbers
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